Medication info
Advonal Tablet

Advonal Tablet

Prescription medicationTabletOral
Ingredient · strength
Risedronate Sodium 2.5 Hydrate›40.162mg / 1 tabletCholecalciferol Concentrate Powder›56mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Pale orange oval film-coated tablets
Packaging
4 tablets (PTP packaging)
Approval status
Active

MFDS item code 201604697 · Approved 2016.07.29 · Insurance code 647804440

Summary

Main use
Treatment and prevention of osteoporosis in postmenopausal women; treatment of osteoporosis in men
Who takes it
Adults · Children
Adult dose
Adults: Administer 1 tablet orally once weekly Older adults: No dose adjustment is necessary because the bioavailability and pharmacokinetics of this medicine in older adults (60 years and older) are similar to those in younger people. Patients with renal impairment: No dose adjustment is necessary for patients with a creatinine clearance of 30ml/min or greater. This medicine is contraindicated in patients with severe renal impairment and a creatinine clearance of less than 30ml/min. Food interferes with the absorption of this medicine, so take it as follows to ensure adequate absorption. Take it at least 30 minutes before breakfast, or at any time of day at least 2 hours before or after consuming food or beverages. To help the medicine reach the stomach easily and reduce the possibility of esophageal irritation, take it while sitting or standing upright with plenty of plain water (170 ~ 230ml). Taking it with other beverages, including mineral water, may reduce the absorption of this medicine. Do not chew or suck this medicine because of the possibility of oropharyngeal ulceration. Patients should also not lie down for at least 30 minutes after taking it. Patients with inadequate calcium and vitamin D intake from food should take supplements. Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, and patients with chronic illnesses) may need additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndrome may require higher doses of vitamin D supplements; measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. Taking this medicine once weekly provides one week’s supply of vitamin D at 800 IU daily. If a patient forgets to take a dose on the scheduled day, take it on the day they remember. Take the next dose again on the originally scheduled day. Do not take 2 tablets on the same day.
Child dose
Children: The safety and efficacy in children and adolescents who are still growing have not been established.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of osteoporosis in postmenopausal women; treatment of osteoporosis in men

  • Osteoporosis
View approved original text

This medication is used to treat and prevent osteoporosis in postmenopausal women and men.

How to take

Adult dose

Adults: Administer 1 tablet orally once weekly Older adults: No dose adjustment is necessary because the bioavailability and pharmacokinetics of this medicine in older adults (60 years and older) are similar to those in younger people. Patients with renal impairment: No dose adjustment is necessary for patients with a creatinine clearance of 30ml/min or greater. This medicine is contraindicated in patients with severe renal impairment and a creatinine clearance of less than 30ml/min. Food interferes with the absorption of this medicine, so take it as follows to ensure adequate absorption. Take it at least 30 minutes before breakfast, or at any time of day at least 2 hours before or after consuming food or beverages. To help the medicine reach the stomach easily and reduce the possibility of esophageal irritation, take it while sitting or standing upright with plenty of plain water (170 ~ 230ml). Taking it with other beverages, including mineral water, may reduce the absorption of this medicine. Do not chew or suck this medicine because of the possibility of oropharyngeal ulceration. Patients should also not lie down for at least 30 minutes after taking it. Patients with inadequate calcium and vitamin D intake from food should take supplements. Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, and patients with chronic illnesses) may need additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndrome may require higher doses of vitamin D supplements; measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. Taking this medicine once weekly provides one week’s supply of vitamin D at 800 IU daily. If a patient forgets to take a dose on the scheduled day, take it on the day they remember. Take the next dose again on the originally scheduled day. Do not take 2 tablets on the same day.

Child dose

Children: The safety and efficacy in children and adolescents who are still growing have not been established.

Precautions

This medication can irritate the gastrointestinal mucosa and may cause esophageal-related issues such as esophagitis, esophageal ulcers, and esophageal erosion. If you experience symptoms such as difficulty swallowing, pain behind the sternum, or heartburn after taking this medication, discontinue use immediately and consult your physician. It is essential to take this medication with a sufficient amount of water (170-230 ml) and to remain upright for at least 30 minutes after taking it. Patients with esophageal strictures or achalasia that delay esophageal clearance, patients with hypocalcemia, and patients with severe renal impairment should not take this medication. Additionally, patients with genetic issues such as lactose intolerance should not be administered this medication. During treatment, it is important to ensure an adequate intake of calcium and vitamin D, and it is advisable not to take this medication with drugs containing calcium or divalent cations. This medication may cause side effects such as osteonecrosis of the jaw, severe bone, joint, and muscle pain, and, rarely, skin rash or hypersensitivity; any unusual symptoms should be reported to a doctor. If pregnant or breastfeeding, it is recommended to discontinue this medication or breastfeeding. Safety in children has not been established, while elderly patients demonstrate similar safety and efficacy to the general adult population. In case of overdose, hypocalcemia may occur, which may require gastric lavage or calcium supplementation if needed. Store this medication out of reach of children and do not transfer it to another container.

Side effects

  • esophagitis
  • esophageal ulcer
  • esophageal erosion
  • esophageal obstruction
  • esophageal perforation
  • bleeding
  • gastric ulcer
  • duodenitis
  • stomatitis
  • hypocalcemia
Show 97 more
  • hypophosphatemia
  • infection
  • lumbago
  • pain
  • abdominal pain
  • neck pain
  • weakness
  • chest pain
  • neoplasm
  • hernia
  • hypertension
  • cardiovascular disease
  • angina
  • nausea
  • diarrhea
  • bloating
  • gastritis
  • gastrointestinal disease
  • rectal disease
  • dental disease
  • petechiae
  • anemia
  • arthralgia
  • joint abnormalities
  • myalgia
  • bone pain
  • bone abnormalities
  • leg cramps
  • bursitis
  • tendon abnormalities
  • depression
  • dizziness
  • insomnia
  • anxiety
  • neuralgia
  • vertigo
  • tension increase
  • sensory abnormalities
  • pharyngitis
  • rhinitis
  • dyspnea
  • pneumonia
  • rash
  • pruritus
  • skin cancer
  • cataract
  • conjunctivitis
  • otitis media
  • urinary tract infection
  • cystitis
  • injury due to accident
  • influenza-like illness
  • headache
  • overdose
  • allergic reaction
  • syncope
  • vasodilation
  • constipation
  • dyspepsia
  • nausea
  • gastroenteritis
  • colitis
  • vomiting
  • polydipsia
  • peripheral edema
  • traumatic fracture
  • myositis
  • arthritis
  • cervical pain
  • asthenia
  • fever
  • falling
  • dizziness
  • bronchitis
  • sinusitis
  • increased cough
  • facial edema
  • alopecia
  • dysosmia
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • angioedema
  • blister
  • jawbone necrosis
  • liver dysfunction
  • jaundice
  • external auditory canal osteonecrosis
  • loss of appetite
  • chest discomfort
  • palpitations
  • increased sweating
  • facial flushing
  • burning sensation
  • nephrolithiasis
  • belching
  • hematuria
  • fever

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. It is advisable to keep it at a temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale orange oval film-coated tablets

Package unit

4 tablets (PTP packaging)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.